BR112017005631A2 - células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 - Google Patents

células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2

Info

Publication number: BR112017005631A2
Authority: BR; Brazil
Prior art keywords: il13ra2; costimulator; cells; antigen receptor; targeted chimeric
Prior art date: 2014-09-19

Application number

BR112017005631-3A

Other languages

English (en)

Inventor

E. BROWN Christine

J. FORMAN Stephen

Original Assignee

City Of Hope

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-19

Filing date

2015-09-18

Publication date

2018-06-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017005631(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-09-18 Application filed by City Of Hope filed Critical City Of Hope

2015-09-18 Priority to BR122024000360-0A priority Critical patent/BR122024000360A2/pt

2018-06-26 Publication of BR112017005631A2 publication Critical patent/BR112017005631A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4217—Receptors for interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BR112017005631-3A 2014-09-19 2015-09-18 células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 BR112017005631A2 (pt)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
BR122024000360-0A BR122024000360A2 (pt)	2014-09-19	2015-09-18	Molécula de ácido nucleico, população de células t humanas transduzidas por um vetor que compreende um cassete de expressão que codifica um receptor de antígeno quimérico e seu uso

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462053068P	2014-09-19	2014-09-19
US62/053,068		2014-09-19
PCT/US2015/051089 WO2016044811A1 (en)	2014-09-19	2015-09-18	COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2

Publications (1)

Publication Number	Publication Date
BR112017005631A2 true BR112017005631A2 (pt)	2018-06-26

Family

ID=55533940

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
BR122024000360-0A BR122024000360A2 (pt)	2014-09-19	2015-09-18	Molécula de ácido nucleico, população de células t humanas transduzidas por um vetor que compreende um cassete de expressão que codifica um receptor de antígeno quimérico e seu uso
BR112017005631-3A BR112017005631A2 (pt)	2014-09-19	2015-09-18	células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
BR112017005630-5A BR112017005630B1 (pt)	2014-09-19	2015-09-21	Uso de uma população de células t humanas transduzidas com um vetor que expressa um receptor de antígeno quimérico e método para a preparação de uma população de células t de memória central

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BR122024000360-0A BR122024000360A2 (pt)	2014-09-19	2015-09-18	Molécula de ácido nucleico, população de células t humanas transduzidas por um vetor que compreende um cassete de expressão que codifica um receptor de antígeno quimérico e seu uso

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BR112017005630-5A BR112017005630B1 (pt)	2014-09-19	2015-09-21	Uso de uma população de células t humanas transduzidas com um vetor que expressa um receptor de antígeno quimérico e método para a preparação de uma população de células t de memória central

Country Status (15)

Country	Link
US (3)	US9914909B2 (pt)
EP (4)	EP3194433B1 (pt)
JP (7)	JP6657195B2 (pt)
KR (3)	KR102683584B1 (pt)
CN (4)	CN113789336A (pt)
AU (4)	AU2015317351B2 (pt)
BR (3)	BR122024000360A2 (pt)
CA (2)	CA2961654A1 (pt)
DK (1)	DK3200591T3 (pt)
ES (2)	ES2738705T3 (pt)
HK (1)	HK1247046A1 (pt)
IL (6)	IL292650B2 (pt)
MX (4)	MX387135B (pt)
RU (2)	RU2749922C2 (pt)
WO (2)	WO2016044811A1 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104619334A (zh)	2012-08-09	2015-05-13	利兰斯坦福初级大学董事会	超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
ES2776698T3 (es)	2012-12-20	2020-07-31	Purdue Research Foundation	Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
US9657105B2 (en)	2013-03-15	2017-05-23	City Of Hope	CD123-specific chimeric antigen receptor redirected T cells and methods of their use
BR122024000360A2 (pt) *	2014-09-19	2024-02-27	City Of Hope	Molécula de ácido nucleico, população de células t humanas transduzidas por um vetor que compreende um cassete de expressão que codifica um receptor de antígeno quimérico e seu uso
AU2016264323B2 (en)	2015-05-18	2021-02-18	TCR2 Therapeutics Inc.	Compositions and methods for TCR reprogramming using fusion proteins
CN108348550A (zh)	2015-07-21	2018-07-31	希望之城公司	用于表达嵌合抗原受体和其它受体的t细胞
KR102011789B1 (ko) *	2015-08-05	2019-08-19	주식회사 셀랩메드	키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포
CA3019650C (en)	2016-04-01	2023-07-25	Kite Pharma, Inc.	Chimeric receptors and methods of use thereof
AU2017240150C1 (en) *	2016-04-01	2022-10-27	Kite Pharma, Inc.	BCMA binding molecules and methods of use thereof
SG11201808622SA (en) *	2016-04-01	2018-10-30	Amgen Inc	Chimeric receptors to flt3 and methods of use thereof
BR112018070073A2 (pt)	2016-04-01	2019-02-12	Kite Pharma, Inc.	receptores de antígeno quimérico e célula t e métodos de uso
EP3439675A4 (en)	2016-04-08	2019-12-18	Purdue Research Foundation	METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
WO2017192536A1 (en)	2016-05-02	2017-11-09	University Of Kansas	Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US12048718B2 (en) *	2016-06-07	2024-07-30	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft	Chimeric antigen receptor and CAR-T cells that bind BCMA
KR102469703B1 (ko) *	2016-06-08	2022-11-23	프레시전 인코포레이티드	Cd33 특이적 키메라 항원 수용체
EP3494138A1 (en)	2016-08-02	2019-06-12	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
CA3036966A1 (en) *	2016-09-16	2018-03-22	Baylor College Of Medicine	Platform for activation and expansion of virus-specific t-cells
WO2018067993A1 (en)	2016-10-07	2018-04-12	TCR2 Therapeutics Inc.	Compositions and methods for t-cell receptors reprogramming using fusion proteins
CN110177803A (zh)	2016-11-22	2019-08-27	T细胞受体治疗公司	用于使用融合蛋白进行tcr重新编程的组合物和方法
WO2018102761A1 (en)	2016-12-02	2018-06-07	City Of Hope	Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
WO2018106972A1 (en) *	2016-12-07	2018-06-14	La Jolla Institute For Allergy And Immunology	Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
WO2018148224A1 (en)	2017-02-07	2018-08-16	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
CN108395481B (zh) *	2017-02-08	2021-02-05	西比曼生物科技（香港）有限公司	一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
US12083148B2 (en) *	2017-02-22	2024-09-10	H. Lee Moffitt Cancer Center And Research Institute, Inc.	IL13Ra2-binding chimeric antigen receptors
EP3589295B1 (en)	2017-02-28	2024-09-11	Endocyte, Inc.	Compositions and methods for car t cell therapy
KR102333377B1 (ko) *	2017-03-27	2021-11-30	노일 이뮨 바이오테크 가부시키가이샤	키메라 항원 수용체
EP3612210A4 (en) *	2017-04-19	2021-01-27	Board Of Regents, The University Of Texas System	IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
CN107267555B (zh) *	2017-05-27	2020-03-20	上海优卡迪生物医药科技有限公司	一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
US12274735B2 (en)	2017-10-10	2025-04-15	Medicenna Therapeutics Inc.	IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
AU2018362014A1 (en) *	2017-11-03	2020-05-28	Sorrento Therapeutics, Inc.	CD38-directed chimeric antigen receptor constructs
US20200345823A1 (en) *	2017-11-07	2020-11-05	Xiuli Wang	Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car
CN109971721B (zh) *	2017-12-28	2023-10-31	上海细胞治疗研究院	自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN109971712B (zh) *	2017-12-28	2023-06-20	上海细胞治疗研究院	特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
US11311576B2 (en)	2018-01-22	2022-04-26	Seattle Children's Hospital	Methods of use for CAR T cells
SG11202007426XA (en)	2018-02-06	2020-09-29	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN111971053A (zh) *	2018-02-12	2020-11-20	综合医院公司	靶向肿瘤微环境的嵌合抗原受体
US12240870B2 (en)	2018-02-23	2025-03-04	Purdue Research Foundation	Sequencing method for CAR T cell therapy
IL314877A (en)	2018-03-14	2024-10-01	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy
BR112020018534A2 (pt) *	2018-03-14	2020-12-29	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Imunoterapia com células t direcionadas por zetacina alvejada por receptor alfa 2 da il-13
US12144826B2 (en)	2018-04-06	2024-11-19	The Regents Of The University Of California	Methods of treating EGFRvIII expressing glioblastomas
EP3773633A4 (en)	2018-04-06	2022-01-26	The Regents of The University of California	METHODS OF TREATMENT OF GLIOBLASTOMA
US20220089718A1 (en) *	2018-05-21	2022-03-24	Biosceptre (Uk) Limited	Chimeric antigen receptors with modified linker domains and uses thereof
US20210214410A1 (en) *	2018-06-01	2021-07-15	The Board Of Trustees Of The Leland Stanford Junior University	Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
CN112638478A (zh)	2018-06-29	2021-04-09	希望之城公司	用于治疗某些自身免疫病症的cd6靶向性嵌合抗原受体
EP3834833A4 (en) *	2018-08-10	2022-05-18	Eutilex Co., Ltd.	Cancer antigen-specific cytotoxic t cells
US20230065784A1 (en)	2019-03-21	2023-03-02	City Of Hope	Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
US20220145252A1 (en)	2019-03-29	2022-05-12	City Of Hope	Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
CN112204135A (zh) *	2019-07-06	2021-01-08	苏州克睿基因生物科技有限公司	一种表达cd3抗体受体复合物的免疫细胞及其用途
WO2021004400A1 (zh) *	2019-07-06	2021-01-14	苏州克睿基因生物科技有限公司	一种表达cd3抗体受体复合物的免疫细胞及其用途
EP4004049A1 (en) *	2019-07-24	2022-06-01	Regeneron Pharmaceuticals, Inc.	Chimeric antigen receptors with mage-a4 specificity and uses thereof
EP3769816A1 (en) *	2019-07-25	2021-01-27	Ospedale Pediatrico Bambino Gesù	Car-cd123 vector and uses thereof
WO2021138454A1 (en)	2019-12-30	2021-07-08	City Of Hope	Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
JP2023512250A (ja) *	2020-01-31	2023-03-24	シティ・オブ・ホープ	ＩＬ１３Ｒα２陽性悪性腫瘍の治療のための標的キメラ抗原受容体修飾Ｔ細胞
WO2021183755A1 (en) *	2020-03-11	2021-09-16	City Of Hope	Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
CN115515971A (zh) *	2020-03-12	2022-12-23	希望之城公司	治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞
WO2021242719A1 (en) *	2020-05-27	2021-12-02	The Medical College Of Wisconsin, Inc.	Improved lentiviral vector transfer plasmid and methods of use
GB202011993D0 (en)	2020-07-31	2020-09-16	Adc Therapeutics Sa	ANTI-IL 13Ra2 antibodies
IL301233A (en) *	2020-09-10	2023-05-01	Mustang Bio Inc	Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer
WO2022109498A1 (en)	2020-11-23	2022-05-27	City Of Hope	Engineered t cells for expression of chimeric anitgen receptors
IL303269A (en)	2020-12-03	2023-07-01	Century Therapeutics Inc	Genetically engineered cells and uses thereof
US11661459B2 (en)	2020-12-03	2023-05-30	Century Therapeutics, Inc.	Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021401052A1 (en)	2020-12-18	2023-06-22	Century Therapeutics, Inc.	Chimeric antigen receptor systems with adaptable receptor specificity
CN114907485B (zh) *	2021-02-08	2024-04-26	浙江大学	一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
US12144827B2 (en)	2021-02-25	2024-11-19	Lyell Immunopharma, Inc.	ROR1 targeting chimeric antigen receptor
EP4308595A4 (en) *	2021-03-18	2025-03-12	The Wistar Institute of Anatomy and Biology	DNA-ENCODED BISPECIFIC ANTIBODIES AGAINST IL13RALPHA2 AND METHODS FOR USE IN CANCER THERAPY
CN117242090A (zh)	2021-03-30	2023-12-15	希望之城公司	CAR T细胞疗法和IFNγ
US20230190799A1 (en) *	2021-07-21	2023-06-22	City Of Hope	Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
CN113621077B (zh) *	2021-09-02	2023-01-31	山东大学	一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
EP4176895A1 (en) *	2021-11-08	2023-05-10	AvenCell Europe GmbH	Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
WO2023130462A1 (zh) *	2022-01-10	2023-07-13	卡瑞济(北京)生命科技有限公司	靶向IL13Rα2的嵌合抗原受体及其用途
CN115960257B (zh) *	2022-09-29	2023-10-27	卡瑞济(北京)生命科技有限公司	靶向IL13Rα2的经优化的嵌合抗原受体及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2096749T3 (es)	1990-12-14	1997-03-16	Cell Genesys Inc	Cadenas quimericas para vias de transduccion de señal asociada a un receptor.
US5712149A (en)	1995-02-03	1998-01-27	Cell Genesys, Inc.	Chimeric receptor molecules for delivery of co-stimulatory signals
NZ337002A (en) *	1995-02-24	2005-07-29	Gen Hospital Corp	Redirection of cellular immunity by receptor chimeras
GB9526131D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Recombinant chimeric receptors
US6576232B1 (en)	1998-04-03	2003-06-10	The Penn State Research Foundation	IL13 mutants
PT1100529E (pt)	1998-07-30	2005-10-31	Us Gov Health & Human Serv	A timosina beta 4 promove a preparacao de feridas
WO2000023573A2 (en)	1998-10-20	2000-04-27	City Of Hope	Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US7560280B2 (en)	2000-11-03	2009-07-14	Kourion Therapeutics Gmbh	Human cord blood derived unrestricted somatic stem cells (USSC)
US7070995B2 (en)	2001-04-11	2006-07-04	City Of Hope	CE7-specific redirected immune cells
AU2002256390B2 (en)	2001-04-30	2007-08-30	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
US20090257994A1 (en)	2001-04-30	2009-10-15	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
US11278594B2 (en) *	2001-04-30	2022-03-22	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) *	2001-04-30	2009-04-07	City Of Hope	Chimeric immunoreceptor useful in treating human gliomas
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US7446190B2 (en)	2002-05-28	2008-11-04	Sloan-Kettering Institute For Cancer Research	Nucleic acids encoding chimeric T cell receptors
ATE373904T1 (de)	2003-07-24	2007-10-15	Matsushita Electric Ind Co Ltd	Verfahren, kodierer und kommunikationsvorrichtung zur kodierung von parallel verketteten daten
US20050113564A1 (en)	2003-11-05	2005-05-26	St. Jude Children's Research Hospital	Chimeric receptors with 4-1BB stimulatory signaling domain
US7754441B2 (en) *	2003-11-17	2010-07-13	Genentech, Inc.	Compositions and methods for the treatment of tumor of hematopoietic origin
DE102004043271A1 (de) *	2004-09-07	2006-03-09	Linde Ag	Verfahren zur Synthese von Zirkoniumcarboxylaten
LT1814580T (lt) *	2004-11-24	2016-12-12	Fred Hutchinson Cancer Research Center	Il 21 naudojimo pritaikomajai imunoterapijai ir naviko antigenų identifikavimo metodai
DE602006017435D1 (de) *	2005-12-21	2010-11-18	Sentoclone Ab	Verfahren zur expansion tumorreaktiver t-lymphozyten zur immuntherapie von patienten mit krebs
CA2634072A1 (en)	2005-12-21	2007-06-28	Universite De Montreal	Markers for memory t cells and uses thereof
DK2126054T3 (en)	2007-01-31	2016-10-03	Yeda Res & Dev	REROUTED, GENETICALLY MODIFIED regulatory T cells and their use for suppressing autoimmune inflammatory disease AND
CA2700714C (en) *	2007-09-26	2018-09-11	Ucb Pharma S.A.	Dual specificity antibody fusions
PT3006459T (pt) *	2008-08-26	2021-11-26	Hope City	Método e composições para funcionamento melhorado de efetores antitumorais de células t
TW201130511A (en) *	2009-12-22	2011-09-16	Novartis Ag	Soluble proteins for use as therapeutics
GB2481983A (en) *	2010-07-12	2012-01-18	Hart Fenton & Co Ltd	A ship including a gas tank room
CA2809255A1 (en) *	2010-08-18	2012-02-23	The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services	Methods of identifying central memory t cells and obtaining antigen-specific t cell populations
PH12013501201A1 (en) *	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
CN106074601A (zh) *	2011-03-23	2016-11-09	弗雷德哈钦森癌症研究中心	用于细胞免疫治疗的方法和组合物
PT2691417T (pt) *	2011-03-29	2018-10-31	Roche Glycart Ag	Variantes de fc de anticorpos
EP2532740A1 (en) *	2011-06-11	2012-12-12	Michael Schmück	Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
AU2013221672B2 (en) *	2012-02-13	2017-11-09	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	Bispecific chimeric antigen receptors and therapeutic uses thereof
US10780118B2 (en) *	2012-08-20	2020-09-22	Fred Hutchinson Cancer Research Center	Method and compositions for cellular immunotherapy
US9657105B2 (en) *	2013-03-15	2017-05-23	City Of Hope	CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP3626748A1 (en) *	2014-01-13	2020-03-25	Stephen J. Forman	Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
BR122024000360A2 (pt)	2014-09-19	2024-02-27	City Of Hope	Molécula de ácido nucleico, população de células t humanas transduzidas por um vetor que compreende um cassete de expressão que codifica um receptor de antígeno quimérico e seu uso

2015
- 2015-09-18 BR BR122024000360-0A patent/BR122024000360A2/pt not_active Application Discontinuation
- 2015-09-18 IL IL292650A patent/IL292650B2/en unknown
- 2015-09-18 EP EP15775539.8A patent/EP3194433B1/en active Active
- 2015-09-18 IL IL308324A patent/IL308324A/en unknown
- 2015-09-18 JP JP2017515139A patent/JP6657195B2/ja active Active
- 2015-09-18 CA CA2961654A patent/CA2961654A1/en active Pending
- 2015-09-18 AU AU2015317351A patent/AU2015317351B2/en active Active
- 2015-09-18 CN CN202110969587.7A patent/CN113789336A/zh active Pending
- 2015-09-18 EP EP19175730.1A patent/EP3587446A1/en active Pending
- 2015-09-18 BR BR112017005631-3A patent/BR112017005631A2/pt active Search and Examination
- 2015-09-18 MX MX2017003596A patent/MX387135B/es unknown
- 2015-09-18 KR KR1020177010183A patent/KR102683584B1/ko active Active
- 2015-09-18 WO PCT/US2015/051089 patent/WO2016044811A1/en active Application Filing
- 2015-09-18 RU RU2017111298A patent/RU2749922C2/ru active
- 2015-09-18 CN CN201580061133.2A patent/CN107002084B/zh active Active
- 2015-09-18 ES ES15775539T patent/ES2738705T3/es active Active
- 2015-09-21 IL IL251188A patent/IL251188B/en unknown
- 2015-09-21 JP JP2017515138A patent/JP6711819B2/ja active Active
- 2015-09-21 DK DK15842405.1T patent/DK3200591T3/da active
- 2015-09-21 EP EP21166086.5A patent/EP3916084A1/en active Pending
- 2015-09-21 MX MX2017003557A patent/MX383042B/es unknown
- 2015-09-21 CN CN201580062281.6A patent/CN107404881B/zh active Active
- 2015-09-21 HK HK18106866.8A patent/HK1247046A1/zh unknown
- 2015-09-21 KR KR1020237041649A patent/KR20230169455A/ko not_active Ceased
- 2015-09-21 BR BR112017005630-5A patent/BR112017005630B1/pt active IP Right Grant
- 2015-09-21 CN CN202110690954.XA patent/CN113637640A/zh active Pending
- 2015-09-21 KR KR1020177010184A patent/KR102610715B1/ko active Active
- 2015-09-21 CA CA2961676A patent/CA2961676A1/en active Pending
- 2015-09-21 ES ES15842405T patent/ES2876235T5/es active Active
- 2015-09-21 WO PCT/US2015/051280 patent/WO2016044853A1/en not_active Application Discontinuation
- 2015-09-21 RU RU2017111300A patent/RU2763523C2/ru active
- 2015-09-21 EP EP15842405.1A patent/EP3200591B2/en active Active
2016
- 2016-05-27 US US15/167,869 patent/US9914909B2/en active Active
2017
- 2017-03-15 IL IL251196A patent/IL251196B/en active IP Right Grant
- 2017-03-16 MX MX2021006400A patent/MX2021006400A/es unknown
- 2017-03-17 MX MX2021012720A patent/MX2021012720A/es unknown
2018
- 2018-03-12 US US15/918,901 patent/US10676717B2/en active Active
2020
- 2020-02-05 JP JP2020017583A patent/JP6986190B2/ja active Active
- 2020-05-06 US US16/867,803 patent/US20200318069A1/en active Pending
- 2020-05-28 JP JP2020093109A patent/JP7216045B2/ja active Active
- 2020-06-03 AU AU2020203651A patent/AU2020203651A1/en not_active Abandoned
2021
- 2021-02-02 IL IL280576A patent/IL280576B/en unknown
- 2021-10-15 JP JP2021169396A patent/JP7171871B2/ja active Active
- 2021-11-30 AU AU2021277651A patent/AU2021277651A1/en not_active Abandoned
2022
- 2022-05-08 IL IL292828A patent/IL292828A/en unknown
- 2022-11-02 JP JP2022176776A patent/JP2023014100A/ja active Pending
2023
- 2023-01-19 JP JP2023006410A patent/JP2023052506A/ja not_active Ceased
2024
- 2024-02-28 AU AU2024201326A patent/AU2024201326A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2016044853A1 (en)	2016-03-24
MX2017003557A (es)	2017-10-12
JP2017529081A (ja)	2017-10-05
MX2021012720A (es)	2022-01-06
IL251196A0 (en)	2017-05-29
JP7171871B2 (ja)	2022-11-15
IL251196B (en)	2021-02-28
WO2016044811A1 (en)	2016-03-24
IL280576B (en)	2022-06-01
JP2020156494A (ja)	2020-10-01
AU2020203651A1 (en)	2020-06-25
US20160340649A1 (en)	2016-11-24
HK1247046A1 (zh)	2018-09-21
RU2017111298A (ru)	2018-10-19
CA2961676A1 (en)	2016-03-24
ES2738705T3 (es)	2020-01-24
ES2876235T3 (es)	2021-11-12
RU2017111300A3 (pt)	2019-09-04
US20200318069A1 (en)	2020-10-08
IL292650B1 (en)	2023-12-01
IL292828A (en)	2022-07-01
US10676717B2 (en)	2020-06-09
JP2022017333A (ja)	2022-01-25
KR102683584B1 (ko)	2024-07-10
EP3194433B1 (en)	2019-05-22
IL308324A (en)	2024-01-01
KR102610715B1 (ko)	2023-12-08
EP3194433A1 (en)	2017-07-26
CN113789336A (zh)	2021-12-14
CN107002084B (zh)	2021-09-10
KR20170054509A (ko)	2017-05-17
NZ730208A (en)	2024-03-22
EP3200591A1 (en)	2017-08-09
JP6711819B2 (ja)	2020-06-17
US9914909B2 (en)	2018-03-13
MX387135B (es)	2025-03-18
CN107404881A (zh)	2017-11-28
KR20170057351A (ko)	2017-05-24
CN107002084A (zh)	2017-08-01
JP2020100626A (ja)	2020-07-02
CA2961654A1 (en)	2016-03-24
RU2017111300A (ru)	2018-10-19
JP7216045B2 (ja)	2023-01-31
DK3200591T3 (da)	2021-06-21
MX2021006400A (es)	2021-07-15
AU2024201326A1 (en)	2024-04-11
AU2015317351B2 (en)	2020-07-02
JP2023052506A (ja)	2023-04-11
BR122024000360A2 (pt)	2024-02-27
BR112017005630A2 (pt)	2018-06-26
EP3200591A4 (en)	2018-04-04
AU2021277651A1 (en)	2021-12-23
CN113637640A (zh)	2021-11-12
JP6657195B2 (ja)	2020-03-04
ES2876235T5 (en)	2025-02-12
BR112017005630B1 (pt)	2023-12-12
RU2749922C2 (ru)	2021-06-21
RU2763523C2 (ru)	2021-12-30
CN107404881B (zh)	2021-07-09
IL292650A (en)	2022-07-01
EP3587446A1 (en)	2020-01-01
IL251188A0 (en)	2017-05-29
JP2023014100A (ja)	2023-01-26
WO2016044853A8 (en)	2017-04-06
EP3200591B1 (en)	2021-03-31
US20180265844A1 (en)	2018-09-20
EP3916084A1 (en)	2021-12-01
IL280576A (en)	2021-03-25
EP3200591B2 (en)	2024-09-25
IL251188B (en)	2022-07-01
JP2017534262A (ja)	2017-11-24
IL292650B2 (en)	2024-04-01
RU2017111298A3 (pt)	2019-03-13
JP6986190B2 (ja)	2021-12-22
AU2015317351A1 (en)	2017-04-06
MX2017003596A (es)	2017-10-20
KR20230169455A (ko)	2023-12-15
MX383042B (es)	2025-03-13

Publication	Publication Date	Title
IL280576B (en)	2022-06-01	Costimulatory chimeric antigen receptor t cells targeting il13ra2
HUE047929T2 (hu)	2020-05-28	Kiméra antigén receptor
BR112017011893A2 (pt)	2018-07-24	células t modificadas no receptor de antígeno quimérico direcionado para cs1
CL2016002196A1 (es)	2018-02-16	Receptor antigénico quimérico
DK3294764T3 (da)	2021-01-25	Kimæriske antigenreceptor sammensætninger
EP3521427A4 (en)	2020-04-22	CO-RECEPTOR OF A FRAGRANCE RECEPTOR
DK3798217T3 (da)	2023-05-22	Piperidin-cxcr7-receptormodulatorer
GB201503742D0 (en)	2015-04-22	Chimeric antigen receptor
SG11201708313QA (en)	2017-11-29	T cell receptor
PL3529267T3 (pl)	2023-11-06	Receptor komórek t
FR3025617B1 (fr)	2016-12-16	Architecture bi-voies
PT3146271T (pt)	2020-12-04	Método para arrefecer uma sala
DK2988086T3 (da)	2021-04-12	Varmeapparat
GB201519900D0 (en)	2015-12-23	Chimeric antigen receptor
FI10873U1 (fi)	2015-05-18	Hybridilämmityslaite
ES1121730Y (es)	2014-11-27	Canon de arcabuz
FI10693U1 (fi)	2014-11-20	Varaava lämmityslaitteisto
ES1121055Y (es)	2014-11-24	Calentador de potitos
TH1601002756A (th)	2017-08-10	ระบบรีฟอร์มมิ่งเชื้อเพลิง
TH1401005100B (th)	2016-05-10	พนักพิงหลัง
UA27788S (uk)	2014-09-10	Губка
FI10517U1 (fi)	2014-06-16	Konstruktioelementti
FI10485U1 (fi)	2014-05-15	Kiuas
UA30012S (uk)	2015-08-10	Губка
UA30014S (uk)	2015-08-10	Губка

Legal Events

Date	Code	Title	Description
2018-10-02	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-09-01	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-10-06	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-08-24	B350	Update of information on the portal [chapter 15.35 patent gazette]
2023-08-08	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2023-10-10	B07C	Technical examination (opinion): republication [chapter 7.3 patent gazette]	Free format text: REPUBLICACAO DO PARECER 7.1 NOTIFICADO NA RPI NO 2744.
2024-02-15	B154	Notification of filing of divisional application [chapter 15.50 patent gazette]	Free format text: O PEDIDO FOI DIVIDIDO NO BR122024000360-0 PROTOCOLO 870240002017 EM 08/01/2024 17:29.